How does inflammation cause Barrett's metaplasia?

被引:43
作者
Colleypriest, Benjamin J. [1 ]
Ward, Stephen G. [2 ]
Tosh, David [1 ]
机构
[1] Univ Bath, Ctr Regenerat Med, Dept Biol & Biochem, Bath BA2 7AY, Avon, England
[2] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
基金
英国医学研究理事会;
关键词
NF-KAPPA-B; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROESOPHAGEAL-REFLUX; ESOPHAGEAL ADENOCARCINOMA; INTESTINAL METAPLASIA; EPITHELIAL-CELLS; HOMEOBOX GENE; SQUAMOUS EPITHELIUM; RISK-FACTOR; BILE-ACIDS;
D O I
10.1016/j.coph.2009.09.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oesophageal adenocarcinoma conveys a poor prognosis and has a rapidly increasing incidence. Similarly, Barrett's metaplasia (a precursor lesion for oesophageal adenocarcinoma) has an increasing incidence. Both oesophageal adenocarcinoma and Barrett's metaplasia are more common in the context of inflammation as a result of acid and bile reflux. The cytokine profile of Barrett's metaplasia is predominantly a T-helper 2 response that contrasts with the T-helper 1 response in normal and inflamed oesophagus and normal intestine. A key transcription factor in the development of Barrett's metaplasia, CDX2, has recently been shown to be induced in response to inflammatory mediators. The mechanism for induction of CDX2 is dependent on nuclear factor kappa B, a crucial transcription factor in the inflammatory response. Understanding the role of oesophageal inflammation will provide important insight into the development of Barrett's metaplasia and oesophageal cancer.
引用
收藏
页码:721 / 726
页数:6
相关论文
共 54 条
[1]  
Bollschweiler E, 2001, CANCER, V92, P549, DOI 10.1002/1097-0142(20010801)92:3<549::AID-CNCR1354>3.0.CO
[2]  
2-L
[3]   Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age [J].
Brown, Linda Morris ;
Devesa, Susan S. ;
Chow, Wong-Ho .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (16) :1184-1187
[4]   Controversies of the cardiac mucosa and Barrett's oesophagus [J].
Chandrasoma, P .
HISTOPATHOLOGY, 2005, 46 (04) :361-373
[5]   Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? [J].
Chandrasoma, P. ;
Wickramasinghe, K. ;
Ma, Y. ;
DeMeester, T. .
DISEASES OF THE ESOPHAGUS, 2007, 20 (01) :36-41
[6]   Retinoic acid-induced glandular differentiation of the oesophagus [J].
Chang, Chih-Long ;
Lao-Sirieix, Pierre ;
Save, Vicki ;
De La Cueva Mendez, Guillermo ;
Laskey, Ron ;
Fitzgerald, Rebecca C. .
GUT, 2007, 56 (07) :906-917
[7]   Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer [J].
Dannenberg, AJ ;
Altorki, NK ;
Boyle, JO ;
Dang, C ;
Howe, LR ;
Weksler, BB ;
Subbararnaiah, K .
LANCET ONCOLOGY, 2001, 2 (09) :544-551
[8]   Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County [J].
Duan, Lei ;
Wu, Anna H. ;
Sullivan-Halley, Jane ;
Bernstein, Leslie .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (01) :126-134
[9]   Activation of the interleukin-6/STAT 3 antiapoptotic pathway in esophageal cells by bile acids and low pH: Relevance to Barrett's esophagus [J].
Dvorak, Katerina ;
Chavarria, Melissa ;
Payne, Claire M. ;
Ramsey, Lois ;
Crowley-Weber, Cara ;
Dvorakova, Barbora ;
Dvorak, Bohuslav ;
Bernstein, Harris ;
Holubec, Hana ;
Sampliner, Richard E. ;
Bernstein, Carol ;
Prasad, Anil ;
Green, Sylvan B. ;
Garewal, Harinder .
CLINICAL CANCER RESEARCH, 2007, 13 (18) :5305-5313
[10]   Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus [J].
Dvorakova, K ;
Payne, CM ;
Ramsey, L ;
Holubec, H ;
Sampliner, R ;
Dominguez, J ;
Dvorak, B ;
Bernstein, H ;
Bernstein, C ;
Prasad, A ;
Fass, R ;
Cui, HY ;
Garewal, H .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :2020-2028